Is femorofemoral crossover bypass an option in claudication?

Annals of Vascular Surgery
Laura CapocciaMarcio da Rocha

Abstract

Since the introduction of femorofemoral crossover bypass by Freeman and Leeds in 1952 (Calif Med 1952;77:229-233), it has been used as an alternative to anatomic surgical reconstruction for unilateral iliac disease. The objective of this review was to summarize results on femorofemoral crossover bypass surgery for disabling claudication from the most recent studies. All publications describing series or registries of patients treated for claudication by femorofemoral crossover bypass were sought through computerized searches of MEDLINE database. Main outcome measures considered for comparisons were primary and secondary patency rates; mortality; complications such as infection, amputation, or loss of function; improving walking distance or ankle-brachial index; Quality of Life (QoL) variations. Six studies met the inclusion criteria. In the considered series, primary interventions were performed with Dacron, polytetrafluoroethylene (PTFE) or autologous vein graft. The number of patients treated for claudication ranged from 66 to 211 in the considered series. One-year primary patency rates ranged from 71.6 to 96%. In two series, 5-year primary patency rates reported were 71.8 and 72%, and in one series secondary patency rate at ...Continue Reading

References

Jun 1, 1987·Journal of Vascular Surgery·P G KalmanJ L Provan
Aug 1, 1986·American Journal of Surgery·D BuchbinderD P Flanigan
Feb 1, 1966·American Journal of Surgery·C D Papadopoulos
Oct 1, 1983·The British Journal of Surgery·J G Mosley, A Marston
May 1, 1994·The British Journal of Surgery·A C GordonJ Collin
Nov 1, 1996·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·M BerceJ H Miller
Mar 22, 2003·Annals of the Royal College of Surgeons of England·Mahesh PaiJack Collin
May 14, 2005·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·Y W KimS Huh
Jun 30, 2006·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·J P EibergT V Schroeder
Dec 5, 2006·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·L NorgrenKenneth Rosenfield
Jan 16, 2007·Journal of Vascular Surgery·L NorgrenUNKNOWN TASC II Working Group
Nov 13, 2007·Journal of Vascular Surgery·Jean-Baptiste RiccoUNKNOWN French University Surgeons Association

❮ Previous
Next ❯

Citations

Jan 10, 2012·Journal of Vascular Surgery·Chetan P HudedDavid H Stone
Jan 24, 2012·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·T Spahos, F Torella
Oct 26, 2016·Journal of Vascular Surgery·Crystal M KavanaghAbdulhameed Aziz
May 28, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Carlos Martínez-GómezGwenael Ferron
Jul 12, 2017·Vascular Specialist International·Keun-Myoung ParkDong-Ik Kim
Jan 4, 2018·Southern Medical Journal·Akinfemi A AkingboyeFrank W Cross

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aneurysm

Aneurysms are outward distensions or bulges that occurs in a weakened wall of blood vessels. Discover the latest research on aneurysms here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.